ReviewFrontiers in medicine2021
A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 88 citations in OpenAlex.
- Recipient-driven and donor-driven determinants of delayed graft function in paired kidney transplantation: evidence from a Chinese cohort.Renal failure · 2026Article
- Quantifying the Association Between Obesity and In-Hospital Outcomes in Adult Scoliosis Surgery: A Nationwide Inpatient Sample Analysis (2016-2021).Journal of clinical medicine · 2026Article
- Artificial intelligence in nephrology: predicting CKD progression and personalizing treatment.International urology and nephrology · 2026Review
- Prevalence of Obesity, Comorbidities, and Eligibility for Pre-Transplant Bariatric Surgery in 275 Patients Awaiting Kidney Transplant at a Single Center in Germany.Annals of transplantation · 2026Article
- Obesity and subclinical kidney injury: a biomarker based assessment in Asian Indian adults.BMC nutrition · 2026Article
- The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities.European cardiology · 2026Review
- Zinc Deficiency Aggravates High-Fat Diet-Induced Renal Injury by Regulating Oxidative Stress and Inflammation via the Nrf2/HO-1 Pathway.Biological trace element research · 2026Article
- A Systematic Review and Meta-Analysis of the Association Between Obesity and Albuminuria in Asian People.International journal of hypertension · 2026Review
- mTOR blockade prevents progressive proteinuria but induces hyperglycaemia in obese Dahl salt-sensitive rats before puberty.Experimental physiology · 2025Article
- Nanoparticle-Delivered Rutin Prevents Metabolic and Oxidative Imbalance in Obesity Triggered by a High-Fat Diet: In Vivo and In Silico Studies.Biomedicines · 2025Article
- Obesity-Related Kidney Disease: A Growing Threat to Renal Health.International journal of molecular sciences · 2025Review
- Age-Specific Clinical and Laboratory Features and Renal Involvement in Children with MIS-C: A Single Tertiary Centre Experience from Vojvodina.Medicina (Kaunas, Lithuania) · 2025Article
- From fat to filter: the effect of adipose tissue-derived signals on kidney function.Nature reviews. Nephrology · 2025Review
- Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real-world study.Journal of diabetes investigation · 2025Article
- ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Body Mass Index in Late Adolescence and Later Life Kidney Outcomes: A Population-Based Cohort Study in Swedish Men.Kidney medicine · 2025Article
- Article
- Efficacy and Safety of Phase 1 of Very Low Energy Ketogenic Therapy (VLEKT) in Subjects with Obesity and Mild Renal Impairment.Nutrients · 2025Article
- Global, regional, and national burdens of chronic kidney disease attributable to high body mass index from 1990 to 2021, with future forecasts up to 2050: a systematic analysis for the global burden of disease study 2021.Frontiers in public health · 2025Article
- A review of the literature on obesity-related chronic kidney disease: a molecular description of gene susceptibility to polymorphisms, noncoding RNAs, and pathophysiology.Archives of medical science : AMS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is one of the epidemics of our era. Its prevalence is higher than 30% in the U.S. and it is estimated to increase by 50% in 2030. Obesity is associated with a higher risk of all-cause mortality and it is known to be a cause of chronic kidney disease (CKD). Typically, obesity-related glomerulopathy (ORG) is ascribed to renal hemodynamic changes that lead to hyperfiltration, albuminuria and, finally, impairment in glomerular filtration rate due to glomerulosclerosis. Though not only hemodynamics are responsible for ORG: adipokines could cause local effects on mesangial and tubular cells and podocytes promoting maladaptive responses to hyperfiltration. Furthermore, hypertension and type 2 diabetes mellitus, two conditions generally associated with obesity, are both amplifiers of obesity injury in the renal parenchyma, as well as complications of overweight. As in the native kidney, obesity is also related to worse outcomes in kidney transplantation. Despite its impact in CKD and cardiovascular morbility and mortality, therapeutic strategies to fight against obesity-related CKD were limited for decades to renin-angiotensin blockade and bariatric surgery for patients who accomplished very restrictive criteria. Last years, different drugs have been approved or are under study for the treatment of obesity. Glucagon-like peptide-1 receptor agonists are promising in obesity-related CKD since they have shown benefits in terms of losing weight in obese patients, as well as preventing the onset of macroalbuminuria and slowing the decline of eGFR in type 2 diabetes. These new families of glucose-lowering drugs are a new frontier to be crossed by nephrologists to stop obesity-related CKD progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.